Fortress Biotech (FBIO) Competitors

Fortress Biotech logo
$1.82 +0.11 (+6.43%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 0.00 (-0.11%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FBIO vs. VNDA, AMRN, LFCR, DRUG, and SIGA

Should you buy Fortress Biotech stock or one of its competitors? Fortress Biotech's main competitors and comparable companies include Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Lifecore Biomedical (LFCR), Bright Minds Biosciences (DRUG), and Siga Technologies (SIGA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Fortress Biotech (NASDAQ:FBIO) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Fortress Biotech currently has a consensus target price of $17.00, suggesting a potential upside of 891.25%. Vanda Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 254.33%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Fortress Biotech has a net margin of 163.32% compared to Vanda Pharmaceuticals' net margin of -119.87%. Fortress Biotech's return on equity of 83.47% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fortress Biotech163.32% 83.47% 42.98%
Vanda Pharmaceuticals -119.87%-62.70%-37.53%

Fortress Biotech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fortress Biotech has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$63.26M0.90$6.82M$2.300.75
Vanda Pharmaceuticals$216.10M1.07-$220.47M-$4.62N/A

In the previous week, Fortress Biotech had 4 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 7 mentions for Fortress Biotech and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.85 beat Fortress Biotech's score of 0.53 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Amarin?

Amarin (NASDAQ:AMRN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Fortress Biotech has a net margin of 163.32% compared to Amarin's net margin of -10.87%. Fortress Biotech's return on equity of 83.47% beat Amarin's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-10.87% -0.52% -0.36%
Fortress Biotech 163.32%83.47%42.98%

Amarin currently has a consensus price target of $13.00, indicating a potential upside of 14.94%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 891.25%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Fortress Biotech has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$213.65M1.12-$38.80M-$0.96N/A
Fortress Biotech$63.26M0.90$6.82M$2.300.75

In the previous week, Fortress Biotech had 3 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Fortress Biotech and 4 mentions for Amarin. Fortress Biotech's average media sentiment score of 0.53 beat Amarin's score of 0.38 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

22.3% of Amarin shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Summary

Fortress Biotech beats Amarin on 14 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Fortress Biotech has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifecore Biomedical$128.87M1.89-$70.51M-$1.86N/A
Fortress Biotech$63.26M0.90$6.82M$2.300.75

In the previous week, Fortress Biotech had 4 more articles in the media than Lifecore Biomedical. MarketBeat recorded 7 mentions for Fortress Biotech and 3 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.60 beat Fortress Biotech's score of 0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifecore Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 1.36%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 891.25%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Lifecore Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Lifecore Biomedical has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Lifecore Biomedical's net margin of -56.80%. Fortress Biotech's return on equity of 83.47% beat Lifecore Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifecore Biomedical-56.80% N/A -29.53%
Fortress Biotech 163.32%83.47%42.98%

Summary

Fortress Biotech beats Lifecore Biomedical on 12 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Fortress Biotech has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright Minds BiosciencesN/AN/A-$8.74M-$2.08N/A
Fortress Biotech$63.26M0.90$6.82M$2.300.75

Fortress Biotech has a net margin of 163.32% compared to Bright Minds Biosciences' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Bright Minds Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Bright Minds BiosciencesN/A -12.46% -12.30%
Fortress Biotech 163.32%83.47%42.98%

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bright Minds Biosciences presently has a consensus price target of $126.29, indicating a potential upside of 458.54%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 891.25%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Bright Minds Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.92
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Fortress Biotech had 5 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Fortress Biotech and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.62 beat Fortress Biotech's score of 0.53 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bright Minds Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bright Minds Biosciences has a beta of -5.11, meaning that its share price is 611% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Fortress Biotech beats Bright Minds Biosciences on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Siga Technologies?

Fortress Biotech (NASDAQ:FBIO) and Siga Technologies (NASDAQ:SIGA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Fortress Biotech has a net margin of 163.32% compared to Siga Technologies' net margin of 1.31%. Fortress Biotech's return on equity of 83.47% beat Siga Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fortress Biotech163.32% 83.47% 42.98%
Siga Technologies 1.31%0.40%0.35%

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Fortress Biotech had 5 more articles in the media than Siga Technologies. MarketBeat recorded 7 mentions for Fortress Biotech and 2 mentions for Siga Technologies. Fortress Biotech's average media sentiment score of 0.53 beat Siga Technologies' score of -0.02 indicating that Fortress Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Siga Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 891.25%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Fortress Biotech is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Siga Technologies has higher revenue and earnings than Fortress Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$63.26M0.90$6.82M$2.300.75
Siga Technologies$94.57M2.17$23.28MN/AN/A

Fortress Biotech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Fortress Biotech beats Siga Technologies on 11 of the 14 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBIO vs. The Competition

MetricFortress BiotechPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$57.70M$13.74B$7.82B$11.74B
Dividend YieldN/A2.58%2.47%4.47%
P/E Ratio0.7926.5832.7626.82
Price / Sales0.977.298.565.70
Price / CashN/A15.6321.0121.90
Price / Book0.355.424.463.72
Net Income$6.82M$2.88B$3.52B$393.10M
7 Day Performance-4.71%-4.10%-5.47%-4.73%
1 Month Performance-2.67%-5.08%-4.57%-7.14%
1 Year Performance-30.27%-7.47%-1.79%-7.51%

Fortress Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBIO
Fortress Biotech
2.5076 of 5 stars
$1.82
+6.4%
$17.00
+834.1%
-34.5%$57.70M$63.26M0.7978
VNDA
Vanda Pharmaceuticals
4.0124 of 5 stars
$4.17
+1.8%
$13.50
+224.1%
-12.4%$251.25M$216.10MN/A533
AMRN
Amarin
1.7952 of 5 stars
$11.58
-1.4%
$13.00
+12.3%
-30.8%$244.57M$213.65MN/A80
LFCR
Lifecore Biomedical
1.3633 of 5 stars
$6.38
+0.1%
$6.50
+2.0%
-19.4%$241.68M$128.87MN/A382
DRUG
Bright Minds Biosciences
2.9749 of 5 stars
$24.53
+1.7%
$126.29
+414.9%
-60.9%$240.23MN/AN/A25

Related Companies and Tools


This page (NASDAQ:FBIO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners